Vaccination has been universally accepted as the most inexpensive and effective method for reducing and preventing human disease. Yet, according to the World Health Organization (WHO), global vaccination rates still leave ~15% of the world's population susceptible to preventable disease, and is expected to lead directly to the death of 1.5 million people in the coming year. Many vaccinations are delivered through direct injection by health care professionals that inherently limits the number of patients that can be treated. Furthermore, injections are painful, expensive, and time consuming, making it difficult to scale up without significant effort. 

Esperovax looks to become the global leader in oral tablet/capsule vaccinations for some of the world's deadliest treatable diseases by leveraging its new oral vaccine platform. Our delivery system will provide billions of doses annually, that can be delivered by mail and consumed directly by the consumer without requiring health professionals intervention. It is this platform that will lead to the significant expansion of vaccination to the most vulnerable and in need, at a fraction of the cost.